GlassScriptPhysician profile
Rafael A Fleites
NPI 1316974744
$2,348.28
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $365 · 2021: $988 · 2022: $737 · 2023: $80.04 · 2024: $13.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.46 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.01 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $352.44 | 2021-2022 | |
| Celgene Corporation | $170.53 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $54.30 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.25 | 2020-2022 | |
| Vivus LLC | $43.72 | 2021-2022 | |
| Daiichi Sankyo INC. | $33.00 | 2019-2021 | |
| Janssen Biotech, INC. | $32.15 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.96 | 2022 | |
| Evoke Pharma, INC. | $16.99 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.44 | 2021 | |
| Ardelyx, INC. | $14.28 | 2022 | |
| Smith+Nephew, INC. | $13.70 | 2024 | Stravix Pl |
| Ferring Pharmaceuticals INC. | $11.10 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Fleites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.